Verinurad | RDEA3170 | CAS#1352792-74-5 | URAT1 Inhibitor

MedKoo Cat#: 326684 | Name: Verinurad

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Verinurad, also known as RDEA3170, is an organic anion transporter URAT1 (SLC22A12) inhibitor, is being developed by Ardea Biosciences (a subsidiary of AstraZeneca) for the treatment of gout and hyperuricaemia.

Chemical Structure

Verinurad

CAS#1352792-74-5

Theoretical Analysis

MedKoo Cat#: 326684

Name: Verinurad

CAS#: 1352792-74-5

Chemical Formula: C20H16N2O2S

Exact Mass: 348.0932

Molecular Weight: 348.42

Elemental Analysis: C, 68.95; H, 4.63; N, 8.04; O, 9.18; S, 9.20

Price and Availability

Size	Price	Availability
25mg	USD 150.00	Ready to ship
50mg	USD 250.00	Ready to ship
100mg	USD 450.00	Ready to ship
200mg	USD 750.00	Ready to ship
500mg	USD 1,150.00	Ready to ship
1g	USD 1,650.00	Ready to ship
2g	USD 2,650.00	Ready to ship
5g	USD 3,850.00	Ready to ship

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

RDEA3170; RDEA-3170; RDEA 3170; Verinurad

IUPAC/Chemical Name

2-((3-(4-cyanonaphthalen-1-yl)pyridin-4-yl)thio)-2-methylpropanoic acid

InChi Key

YYBOLPLTQDKXPM-UHFFFAOYSA-N

InChi Code

InChI=1S/C20H16N2O2S/c1-20(2,19(23)24)25-18-9-10-22-12-17(18)16-8-7-13(11-21)14-5-3-4-6-15(14)16/h3-10,12H,1-2H3,(H,23,24)

SMILES Code

CC(C)(SC1=C(C2=C3C=CC=CC3=C(C#N)C=C2)C=NC=C1)C(O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Certificate of Analysis

View CoA: current batch, Lot#A8T08K08

QC Data

View QC data: current batch, Lot#A8T08K08

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 348.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Torodii D, Holmes JB, Moutzouri P, Nilsson Lill SO, Cordova M, Pinon AC, Grohe K, Wegner S, Putra OD, Norberg S, Welinder A, Schantz S, Emsley L. Crystal structure validation of verinurad via proton-detected ultra-fast MAS NMR and machine learning. Faraday Discuss. 2025 Jan 8;255(0):143-158. doi: 10.1039/d4fd00076e. PMID: 39297322; PMCID: PMC11411500. 2: Dai Y, Lee CH. Transport mechanism and structural pharmacology of human urate transporter URAT1. Cell Res. 2024 Nov;34(11):776-787. doi: 10.1038/s41422-024-01023-1. Epub 2024 Sep 9. PMID: 39245778; PMCID: PMC11528023. 3: Kitzman DW, Voors AA, Mentz RJ, Lewis GD, Perl S, Myte R, Kaguthi G, Sjöström CD, Källgren C, Shah SJ. Verinurad Plus Allopurinol for Heart Failure With Preserved Ejection Fraction: The AMETHYST Randomized Clinical Trial. JAMA Cardiol. 2024 Oct 1;9(10):892-900. doi: 10.1001/jamacardio.2024.2435. PMID: 39141378; PMCID: PMC11325246. 4: Heerspink HJL, Stack AG, Terkeltaub R, Jongs N, Inker LA, Bjursell M, Maklad N, Perl S, Eklund O, Rikte T, Sjöström CD, Perkovic V; SAPPHIRE Investigators. Combination Treatment with Verinurad and Allopurinol in CKD: A Randomized Placebo and Active Controlled Trial. J Am Soc Nephrol. 2024 May 1;35(5):594-606. doi: 10.1681/ASN.0000000000000326. Epub 2024 Feb 20. PMID: 38564654; PMCID: PMC11149044. 5: Du C, Yin H, Xie A, Yu J, Wang Y, Yao F, Zhang S, Zhang Y, Liu L, Wang P, Dong J, Xu X. Virtual screening and biological evaluation of natural products as urate transporter 1 (URAT1) inhibitors. J Biomol Struct Dyn. 2024 Mar 29:1-14. doi: 10.1080/07391102.2024.2331101. Epub ahead of print. PMID: 38553409. 6: Qu Y, Yu Y, Pan J, Li H, Cui C, Liu D. Systematic review and model-based analysis to identify whether renal safety risks of URAT1 inhibitors are fully determined by uric acid-lowering efficacies. Semin Arthritis Rheum. 2023 Dec;63:152279. doi: 10.1016/j.semarthrit.2023.152279. Epub 2023 Oct 13. PMID: 37866004. 7: Parkinson J, Dota C, Källgren C, Gottfridsson C, Bjursell M, Perl S, Kӧrnicke T, Rekić D, Johansson S. Verinurad does not prolong QTc interval: a thorough QT study using concentration-QTc modelling. Br J Clin Pharmacol. 2023 Jun;89(6):1747-1755. doi: 10.1111/bcp.15637. Epub 2023 Jan 2. PMID: 36504291. 8: Kang EH. Considerations for Choosing First-Line Urate-Lowering Treatment in Older Patients with Comorbid Conditions. Drugs Aging. 2022 Dec;39(12):923-933. doi: 10.1007/s40266-022-00986-3. Epub 2022 Nov 28. PMID: 36437395. 9: Li YJ, Chen LR, Yang ZL, Wang P, Jiang FF, Guo Y, Qian K, Yang M, Yin SJ, He GH. Comparative efficacy and safety of uricosuric agents in the treatment of gout or hyperuricemia: a systematic review and network meta-analysis. Clin Rheumatol. 2023 Jan;42(1):215-224. doi: 10.1007/s10067-022-06356-z. Epub 2022 Aug 29. PMID: 36036279. 10: Guo Z, Yuan W, Zhu X, Jiang Z, Zhang Z, Huang X. UHPLC-MS/MS-based method for quantification of verinurad in rat plasma and its application in a bioavailability study. Biomed Chromatogr. 2022 Nov;36(11):e5471. doi: 10.1002/bmc.5471. Epub 2022 Aug 13. PMID: 35916119. 11: Johansson S, Han D, Hunt T, Björck K, Florica D, Gillen M, Hall J, Erlandsson F. Pharmacokinetics, pharmacodynamics, and safety of verinurad with and without allopurinol in healthy Asian, Chinese, and non-Asian participants. Pharmacol Res Perspect. 2022 Jun;10(3):e00929. doi: 10.1002/prp2.929. PMID: 35593744; PMCID: PMC9121888. 12: Zhao Z, Liu J, Kuang P, Luo J, Surineni G, Cen X, Wu T, Cao Y, Zhou P, Pang J, Zhang Q, Chen J. Discovery of novel verinurad analogs as dual inhibitors of URAT1 and GLUT9 with improved Druggability for the treatment of hyperuricemia. Eur J Med Chem. 2022 Feb 5;229:114092. doi: 10.1016/j.ejmech.2021.114092. Epub 2021 Dec 30. PMID: 34998055. 13: Blake KEG, Saag JL, Saag KG. What's new on the front-line of gout pharmacotherapy? Expert Opin Pharmacother. 2022 Mar;23(4):453-464. doi: 10.1080/14656566.2021.2020249. Epub 2022 Jan 5. PMID: 34935576. 14: Chen X, Zhao Z, Luo J, Wu T, Shen Y, Chang S, Wan S, Li Z, Zhang J, Pang J, Tian Y. Novel natural scaffold as hURAT1 inhibitor identified by 3D-shape-based, docking-based virtual screening approach and biological evaluation. Bioorg Chem. 2021 Dec;117:105444. doi: 10.1016/j.bioorg.2021.105444. Epub 2021 Nov 5. PMID: 34775203. 15: Fogacci F, Borghi C, Di Micoli A, Degli Esposti D, Cicero AFG. Inequalities in enrollment of women and racial minorities in trials testing uric acid lowering drugs. Nutr Metab Cardiovasc Dis. 2021 Nov 29;31(12):3305-3313. doi: 10.1016/j.numecd.2021.09.011. Epub 2021 Sep 20. PMID: 34656384. 16: Jansen TL, Tanja G, Matthijs J. A historical journey of searching for uricosuric drugs. Clin Rheumatol. 2022 Jan;41(1):297-305. doi: 10.1007/s10067-021-05930-1. Epub 2021 Sep 28. PMID: 34581891. 17: Heerspink HJL, Stack AG, Terkeltaub R, Greene TA, Inker LA, Bjursell M, Perl S, Rikte T, Erlandsson F, Perkovic V. Rationale, design, demographics and baseline characteristics of the randomized, controlled, Phase 2b SAPPHIRE study of verinurad plus allopurinol in patients with chronic kidney disease and hyperuricaemia. Nephrol Dial Transplant. 2022 Jul 26;37(8):1461-1471. doi: 10.1093/ndt/gfab237. PMID: 34383954; PMCID: PMC9317164. 18: Fernandez-Prado R, Ortiz A. Verinurad/Febuxostat and Nephrotoxicity. Am J Kidney Dis. 2021 Sep;78(3):468. doi: 10.1053/j.ajkd.2021.03.029. Epub 2021 Jun 11. PMID: 34126127. 19: Stack AG, Erlandsson F, Terkeltaub R. In Reply to 'Verinurad/Febuxostat and Nephrotoxicity'. Am J Kidney Dis. 2021 Sep;78(3):468-469. doi: 10.1053/j.ajkd.2021.05.009. Epub 2021 Jun 11. PMID: 34126126. 20: Gopaul VS, Vildhede A, Andersson TB, Erlandsson F, Lee CA, Johansson S, Hilgendorf C. In Vitro Assessment of the Drug-Drug Interaction Potential of Verinurad and Its Metabolites as Substrates and Inhibitors of Metabolizing Enzymes and Drug Transporters. J Pharmacol Exp Ther. 2021 Aug;378(2):108-123. doi: 10.1124/jpet.121.000549. Epub 2021 Jun 1. PMID: 34074714.